GSA Capital Partners LLP Takes Position in Amgen Inc. (NASDAQ:AMGN)

GSA Capital Partners LLP purchased a new position in Amgen Inc. (NASDAQ:AMGN) during the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund purchased 2,720 shares of the medical research company’s stock, valued at approximately $876,000.

A number of other institutional investors and hedge funds have also recently bought and sold shares of AMGN. M&G Plc bought a new stake in shares of Amgen in the first quarter worth $7,633,000. Patten & Patten Inc. TN raised its stake in shares of Amgen by 4.6% in the 1st quarter. Patten & Patten Inc. TN now owns 3,104 shares of the medical research company’s stock valued at $883,000 after purchasing an additional 136 shares in the last quarter. Edgestream Partners L.P. lifted its position in shares of Amgen by 218.0% during the first quarter. Edgestream Partners L.P. now owns 12,434 shares of the medical research company’s stock worth $3,535,000 after purchasing an additional 8,524 shares during the last quarter. Hillsdale Investment Management Inc. grew its stake in Amgen by 44.3% in the first quarter. Hillsdale Investment Management Inc. now owns 1,400 shares of the medical research company’s stock worth $398,000 after purchasing an additional 430 shares in the last quarter. Finally, Trustmark National Bank Trust Department increased its holdings in Amgen by 6.5% in the first quarter. Trustmark National Bank Trust Department now owns 31,204 shares of the medical research company’s stock valued at $8,872,000 after buying an additional 1,909 shares during the last quarter. Hedge funds and other institutional investors own 76.50% of the company’s stock.

Amgen Stock Down 4.2 %

Amgen stock opened at $283.61 on Friday. The company’s 50-day moving average price is $320.85 and its two-hundred day moving average price is $318.05. The stock has a market cap of $152.45 billion, a price-to-earnings ratio of 36.31, a PEG ratio of 2.69 and a beta of 0.60. Amgen Inc. has a 52 week low of $260.52 and a 52 week high of $346.85. The company has a current ratio of 1.32, a quick ratio of 0.96 and a debt-to-equity ratio of 7.55.

Amgen (NASDAQ:AMGN) last announced its earnings results on Wednesday, October 30th. The medical research company reported $5.58 EPS for the quarter, topping the consensus estimate of $5.11 by $0.47. The firm had revenue of $8.50 billion for the quarter, compared to analysts’ expectations of $8.50 billion. Amgen had a return on equity of 168.35% and a net margin of 13.00%. The firm’s quarterly revenue was up 23.2% compared to the same quarter last year. During the same quarter in the previous year, the company earned $4.96 earnings per share. On average, analysts expect that Amgen Inc. will post 19.51 EPS for the current fiscal year.

Amgen Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Monday, December 9th. Investors of record on Monday, November 18th will be paid a dividend of $2.25 per share. The ex-dividend date is Monday, November 18th. This represents a $9.00 annualized dividend and a yield of 3.17%. Amgen’s dividend payout ratio is currently 115.24%.

Wall Street Analysts Forecast Growth

Several research analysts have recently commented on the company. UBS Group decreased their target price on Amgen from $335.00 to $326.00 and set a “neutral” rating for the company in a research report on Thursday, October 31st. Royal Bank of Canada reiterated an “outperform” rating and set a $362.00 target price on shares of Amgen in a research note on Thursday, September 26th. Dbs Bank upgraded shares of Amgen to a “strong-buy” rating in a research report on Monday, September 16th. Barclays boosted their price objective on shares of Amgen from $300.00 to $315.00 and gave the company an “equal weight” rating in a research report on Monday, October 7th. Finally, Deutsche Bank Aktiengesellschaft reissued a “hold” rating and issued a $305.00 target price (down previously from $310.00) on shares of Amgen in a report on Wednesday, August 7th. One analyst has rated the stock with a sell rating, thirteen have given a hold rating, eleven have assigned a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat, Amgen presently has a consensus rating of “Moderate Buy” and a consensus price target of $333.57.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.